Tocagen

Fighting Cancer with Selective Immunotherapy                                   

Accelerate Brain Cancer Cure was the first non-profit organization to fund Tocagen’s next generation therapeutic for treating brain cancer using selective immunotherapeutic products that are based on gene therapy technology.

Tocagen is initially focused on developing a treatment for an aggressive type of brain cancer, namely recurrent High Grade Glioma (HGG), which includes Glioblastoma Multiforme (GBM) and anaplastic astrocytomas. Potential future indications may include metastatic cancers including melanoma and colorectal cancer.

Tocagen's Treatment Approach

Tocagen’s approach uses a virus that is designed to selectively infect and kill cancer cells without harming healthy cells.  The treatment involves a dual mechanism of action:

1) The Toca 511 virus selectively infects and mediates direct cancer cell killing via local production of 5-FU, a potent anticancer agent, and

2) the immune system becomes activated selectively against the tumor resulting in long-term, systemic anticancer activity.  

Click HERE to learn more about Tocagen's Clinical Trials